Search

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Travel grants

Travel grant submission is now closed

Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and reside in one of the upper-middle, lower-middle, and low-income countries.

SWG Grant-funded projects, 2023

In November and December of 2022, SWGs were invited to develop project ideas and apply for a 2023 SWG Grant. ApplicationsWe received nine different applications from six SWGs.

EHA Research Grants

The call for applications will close on October 15, 2024, at 15:00 (CEST).

Registration & accommodation

Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.